ANKE BIO(SZ:300009) Zheng Quan Shi Bao Wang·2025-11-11 13:17Core Viewpoint - Anke Bio plans to invest 30 million yuan in a stake in Boshengji Pharmaceutical Technology, while also establishing an exclusive agency agreement for the PA3-17 injection product in Greater China [1][2] Group 1: Investment and Stake - Anke Bio will increase its stake in Boshengji from approximately 20% to 21.41% after the investment [1] - The pre-investment valuation of Boshengji is set at 1.74 billion yuan, consistent with its post-investment valuation from the previous financing round in December 2021 [1] Group 2: Product Collaboration - Anke Bio will act as the exclusive agent for the PA3-17 injection product in the Greater China market, with a formal agreement to be signed after the product's market application [2][3] - Boshengji has committed to prioritizing Anke Bio as the exclusive agency for future product launches [3] Group 3: Product Details and Market Potential - PA3-17 is the first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, aimed at treating adult relapsed and refractory CD7-positive hematological malignancies [3] - The product utilizes a non-gene editing strategy to address industry challenges and has established a new quality control system [3] - The market for follicle-stimulating hormone is projected to exceed 4 billion yuan by 2025, with Anke Bio aiming to capture market share quickly [4] Group 4: Financial Performance - In Q3, Anke Bio reported a revenue of 670 million yuan, a year-on-year increase of 7.7%, and a net profit of 185 million yuan, up 6.56% year-on-year [4]